JP Morgan Downgrades Atara Biotherapeutics to Neutral, Lowers Price Target to $22

JP Morgan downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Overweight to Neutral and lowers the price target from $43 to $22.

Benzinga · 11/08/2019 11:14

JP Morgan downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Overweight to Neutral and lowers the price target from $43 to $22.